Stay updated on Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A new history entry dated 2025-01-27 was added to the Record History. No substantive changes to the study record content, statuses, or data were observed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-03T01:34:13.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    32 days ago
    Change Detected
    Summary
    Major update: adds a government funding and operating status notice and marks the page as revision v3.2.0, replacing v3.1.0.
    Difference
    11%
    Check dated 2025-10-05T12:52:01.000Z thumbnail image
  4. Check
    39 days ago
    Change Detected
    Summary
    Update: revision tag changed from v3.0.2 to v3.1.0. No other content changes detected.
    Difference
    0.3%
    Check dated 2025-09-28T09:28:20.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    Updated the page from Revision: v3.0.1 to v3.0.2 and removed the old tag and a Back to Top link, signaling a routine version bump with minor UI cleanup.
    Difference
    0.6%
    Check dated 2025-09-14T00:08:08.000Z thumbnail image
  6. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.6%
    Check dated 2025-09-06T17:49:13.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location details, while removing specific location terms and country listings. This indicates a shift towards a more streamlined presentation of study-related information.
    Difference
    32%
    Check dated 2025-08-30T15:26:29.000Z thumbnail image

Stay in the know with updates to Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Neratinib±Fulvestrant in HER2+/ER+ Metastatic Breast Cancer Clinical Trial page.